Literature DB >> 19682321

Intrathecal ziconotide for neuropathic pain: a review.

Richard L Rauck1, Mark S Wallace, Allen W Burton, Leonardo Kapural, James M North.   

Abstract

Neuropathic pain is a considerable burden that affects activities of daily living. The management of neuropathic pain can be challenging because of multiple etiologies and complex manifestations. Ziconotide is a nonopioid intrathecal (IT) analgesic option for patients with neuropathic pain refractory to conventional treatments. The objective of this article is to review the published literature on ziconotide for the treatment of neuropathic pain. Relevant publications were identified through searches of all years of 6 databases, which included PubMed, EMBASE, and CINAHL. Search terms used were ziconotide, SNX-111, MVIIA, Prialt, and neuropathic pain. Publications were included if ziconotide was intrathecally administered (either alone or in combination with other IT agents) to treat neuropathic pain of any etiology and if pain assessment was an outcome measure. Data extracted included study design, IT drug doses, pain outcome measures, and adverse events (AEs). Twenty-eight articles met the inclusion criteria: 5 were preclinical studies and 23 were clinical studies. In the preclinical studies, ziconotide demonstrated antiallodynic effects on neuropathic pain. Data from double-blind, placebo-controlled (DBPC) trials indicated that patients with neuropathic pain reported a mean percent improvement in pain score with ziconotide monotherapy that ranged from 15.7% to 31.6%. A low starting dose and slow titration of ziconotide resulted in an improved safety profile in the aforementioned trials. Common AEs associated with ziconotide include nausea and/or vomiting, dizziness, confusion, urinary retention, and somnolence. Evidence from DBPC trials, open-label studies, case series, and case studies suggests that ziconotide, as either monotherapy or in combination with other IT drugs, is a potential therapeutic option for patients with refractory neuropathic pain. Additional studies are needed to establish the long-term efficacy and safety of ziconotide for neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19682321     DOI: 10.1111/j.1533-2500.2009.00303.x

Source DB:  PubMed          Journal:  Pain Pract        ISSN: 1530-7085            Impact factor:   3.183


  28 in total

1.  [Experience in treatment of patients with neuropathic facial pain using ziconotide].

Authors:  E A Lux; D Rasche
Journal:  Schmerz       Date:  2011-08       Impact factor: 1.107

2.  Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca²⁺ channel complex.

Authors:  Joel M Brittain; Djane B Duarte; Sarah M Wilson; Weiguo Zhu; Carrie Ballard; Philip L Johnson; Naikui Liu; Wenhui Xiong; Matthew S Ripsch; Yuying Wang; Jill C Fehrenbacher; Stephanie D Fitz; May Khanna; Chul-Kyu Park; Brian S Schmutzler; Bo Myung Cheon; Michael R Due; Tatiana Brustovetsky; Nicole M Ashpole; Andy Hudmon; Samy O Meroueh; Cynthia M Hingtgen; Nickolay Brustovetsky; Ru-Rong Ji; Joyce H Hurley; Xiaoming Jin; Anantha Shekhar; Xiao-Ming Xu; Gerry S Oxford; Michael R Vasko; Fletcher A White; Rajesh Khanna
Journal:  Nat Med       Date:  2011-06-05       Impact factor: 53.440

3.  Pain therapeutics from cone snail venoms: From Ziconotide to novel non-opioid pathways.

Authors:  Helena Safavi-Hemami; Shane E Brogan; Baldomero M Olivera
Journal:  J Proteomics       Date:  2018-05-16       Impact factor: 4.044

4.  Ion Mobility-Mass Spectrometry as a Tool for the Structural Characterization of Peptides Bearing Intramolecular Disulfide Bond(s).

Authors:  Philippe Massonnet; Jean R N Haler; Gregory Upert; Michel Degueldre; Denis Morsa; Nicolas Smargiasso; Gilles Mourier; Nicolas Gilles; Loïc Quinton; Edwin De Pauw
Journal:  J Am Soc Mass Spectrom       Date:  2016-08-03       Impact factor: 3.109

Review 5.  High-value compounds from the molluscs of marine and estuarine ecosystems as prospective functional food ingredients: An overview.

Authors:  Kajal Chakraborty; Minju Joy
Journal:  Food Res Int       Date:  2020-08-31       Impact factor: 6.475

Review 6.  Pain channelopathies.

Authors:  Roman Cregg; Aliakmal Momin; Francois Rugiero; John N Wood; Jing Zhao
Journal:  J Physiol       Date:  2010-02-08       Impact factor: 5.182

Review 7.  Challenging the catechism of therapeutics for chronic neuropathic pain: Targeting CaV2.2 interactions with CRMP2 peptides.

Authors:  Polina Feldman; Rajesh Khanna
Journal:  Neurosci Lett       Date:  2013-07-03       Impact factor: 3.046

Review 8.  Update on neuropathic pain treatment: ion channel blockers and gabapentinoids.

Authors:  Lucy Chen; Jianren Mao
Journal:  Curr Pain Headache Rep       Date:  2013-09

Review 9.  Evaluation of reward from pain relief.

Authors:  Edita Navratilova; Jennifer Yanhua Xie; Tamara King; Frank Porreca
Journal:  Ann N Y Acad Sci       Date:  2013-03-15       Impact factor: 5.691

Review 10.  Cellular and molecular mechanisms of pain.

Authors:  Allan I Basbaum; Diana M Bautista; Grégory Scherrer; David Julius
Journal:  Cell       Date:  2009-10-16       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.